The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?

Abstract

Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder clinically defined by cytopenias, bone marrow failure, and an increased risk of progressing to acute myeloid leukemia (AML). Traditionally, first-line treatment for patients with higher-risk MDS has been hypomethylating agents (HMAs). However, these agents have modest clinical activity as single agents. A one-size-fits-all treatment paradigm is insufficient for such a heterogeneous disease in the modern era of precision medicine. Several new agents have been developed for MDS with the hopes of improving clinical outcomes and survival. Pevonedistat is a first-in-class, novel inhibitor of neuronal precursor cell-expressed developmentally down-regulated protein-8 (NEDD8) activating enzyme (NAE) blocking the neddylation pathway leading to downstream effects on the ubiquitin–proteosome pathway. Pevonedistat ultimately leads to apoptosis and inhibition of the cell cycle in cancer cells. Studies have demonstrated the safety profile of pevonedistat, leading to the development of multiple trials investigating combination strategies with pevonedistat in MDS and AML. In this review, we summarize the preclinical and clinical rationale for pevonedistat in MDS and AML, review the clinical data of this agent alone and in combination with HMAs to date, and highlight potential future directions for this agent in myeloid malignancies.

Targeting Apoptosis in AML: Where Do We Stand?

“…Pevonedistat (TAK-924/MLN4924) is an inhibitor of the NEDD8 activating enzyme (NAE), which suppresses neddylation and induces cell cycle arrest and apoptosis [ 139 ]. Moreover, it increases the accumulation of the pro-apoptotic protein NOXA, as well as the upregulation of PUMA, BIK, and BIM [ 140 , 141 , 142 ]. However, the phase III PANTHER study (NCT03268954) of pevonedistat plus azacitidine ( n = 227) vs azacitidine ( n = 227) in patients with newly diagnosed higher-risk MDS, higher-risk chronic myelomonocytic leukemia, or AML with 20–30% blasts, failed to reach pre-defined statistical significance for the primary endpoint of event-free survival (EFS) [ 143 ].…”

Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review

“…MDS is generally recognized as a myeloid malignancy that usually occurs at an older age. 29 In a report by Candoni et al 30 , AML or MDS-contracted patients who were under treatment showed favorable seroconversion following the first 2 doses of the COVID-19 vaccine. More importantly, a large population of the selected patients experienced an alleviated seroconversion following the second dose of vaccination.…”